Latest Market Entry News

De.mem Limited has reported its strongest December quarter yet, with record cash receipts and a positive operating cash flow for the full year, underpinned by recurring revenues and strategic expansion into the gold mining sector.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

Lotus Resources has made significant progress resolving sulphuric acid supply issues critical to ramping up production at its Kayelekera Uranium Mine, though full steady-state output is now expected in the second quarter of 2026.

Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.

X2M Connect Limited reported a robust second quarter for FY26, with revenues climbing 65% and a notable narrowing of EBITDA losses, driven by strategic expansions in South Korea, Japan, and beyond.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

RLF AgTech Ltd has reported a record December quarter with $10.4 million in cash receipts, driven by strong performances across its LiquaForce, China, and newly operational Australian divisions. Positive field trial results in Vietnam and ongoing expansion in Southeast Asia underpin the company’s growth outlook.

Energy Transition Minerals Ltd (ETM) reported key progress in its December 2025 quarter, including legal developments for its Greenland rare earth project, advancing a strategic mine acquisition in Spain, and moves toward a US Nasdaq listing.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.